HPQ
63
6
NKE
36
6
ORCL
65
-2
AVY
53
3
STZ
54
-3
EQIX
64
2
DOW
44
10
SLB
55
2
PM
62
-2
HD
57
2
SE
61
-4
CFG
70
6
EFX
38
2
URI
65
5
FE
50
-2
ADT
53
3
LLY
37
-3
MRK
25
-2
M
37
12
PPL
54
-5
HPQ
63
6
NKE
36
6
ORCL
65
-2
AVY
53
3
STZ
54
-3
EQIX
64
2
DOW
44
10
SLB
55
2
PM
62
-2
HD
57
2
SE
61
-4
CFG
70
6
EFX
38
2
URI
65
5
FE
50
-2
ADT
53
3
LLY
37
-3
MRK
25
-2
M
37
12
PPL
54
-5
Financhill
Back

Emergent BioSolutions 10K Form

Sell
45

EBS
Emergent BioSolutions

Last Price:
9.48
Seasonality Move:
13.84%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2024-05-02 10Q EBS/Emergent BioSolutions Quarterly
2023-12-11 10Q EBS/Emergent BioSolutions Quarterly
2023-08-09 10Q EBS/Emergent BioSolutions Quarterly
2023-05-10 10Q EBS/Emergent BioSolutions Quarterly
2022-11-09 10Q EBS/Emergent BioSolutions Quarterly
2022-08-02 10Q EBS/Emergent BioSolutions Quarterly

Receive EBS News And Ratings

See the #1 stock for the next 7 days that we like better than EBS

EBS Financial Statistics

Sales & Book Value

Annual Sales: $1.02B
Cash Flow: $147.9M
Price / Cash Flow: 3.65
Annual Sales: $9.40
Price / Book: 1.01

Profitability

EPS (TTM): -4.10000
Net Income (TTM): $-208.8M
Gross Margin: $317.6M
Return on Equity: -35.94%
Return on Assets: -12.27%

Emergent BioSolutions Earnings Forecast

Key Emergent BioSolutions Financial Ratios

  • The Gross Profit Margin over the past 22 years for EBS is 31.05%.
  • The Selling, General & Administrative Expenses for EBS have been equal to 36.01% of Gross Profit Margin.
  • The Research & Development expenses have been 10.89% of Revenue.
  • The Interest Expense is -11.56% of Operating Income.
  • The Net Earning history of EBS is -74.34% of Total Revenues.
  • Per Share Earnings over the last 23 years have been positive in 12 years.

Emergent BioSolutions Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Biotechnology
Sector: Health Care
Current Symbol: EBS
CUSIP: 29089Q
Website: emergentbiosolutions.com

Debt

Debt-to-Equity Ratio: 1.3
Current Ratio: 2.88
Quick Ratio: 1.18

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 3.17

EBS Technical Analysis vs Fundamental Analysis

Sell
45
Emergent BioSolutions (EBS) is a Sell

Is Emergent BioSolutions a Buy or a Sell?